Invion Limited (IVX.AX)
Invion Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $0.04, up 0.00% on the session, giving a market capitalisation of $4.1M. Its beta of 0.43 implies it has historically moved less than the broad market.
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
Invion Limited is most often compared with the following Healthcare names: